Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,817,224 papers from all fields of science
Search
Sign In
Create Free Account
Picoplatin
Known as:
Platinum, Amminedichloro(2-methylpyridine)-, (SP-4-3)
, Cis-Amminedichloro (2-Methylpyridine) Platinum
, Platinum, Amminedichloro(2-methylpyridine)-, (SP-4-3)-
Expand
A new generation organic platinum analog with an extended spectrum of antineoplastic activity. Designed to overcome platinum drug resistance…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Narrower (2)
AMD 473
ZD 0473
JM-473
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.
A. Chang
Lung cancer
2011
Corpus ID: 20309798
Review
2011
Review
2011
Platinum anticancer drugs. From serendipity to rational design.
C. Monneret
Annales pharmaceutiques francaises
2011
Corpus ID: 42607925
Review
2011
Review
2011
Current management of small cell lung cancer.
J. Neal
,
M. Gubens
,
H. Wakelee
Clinics in chest medicine
2011
Corpus ID: 89657
Highly Cited
2010
Highly Cited
2010
The status of platinum anticancer drugs in the clinic and in clinical trials.
N. Wheate
,
Shonagh Walker
,
Gemma E Craig
,
Rabbab Oun
Dalton transactions
2010
Corpus ID: 205766376
Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian…
Expand
Highly Cited
2010
Highly Cited
2010
Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue
Swati S. More
,
Shuanglian Li
,
+4 authors
K. Giacomini
Molecular Cancer Therapeutics
2010
Corpus ID: 18522600
Picoplatin, a third-generation platinum agent, is efficacious against lung cancers that are otherwise resistant or become…
Expand
Review
2010
Review
2010
A better platinum-based anticancer drug yet to come?
U. Olszewski
,
G. Hamilton
Anti-cancer agents in medicinal chemistry
2010
Corpus ID: 43450143
In attempts to overcome the drawbacks of cisplatin - severe toxicity, drug resistance and poor oral bioavailability - the…
Expand
Highly Cited
2009
Highly Cited
2009
Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.
J. Eckardt
,
D. Bentsion
,
+5 authors
H. Breitz
Journal of clinical oncology : official journal…
2009
Corpus ID: 42740181
PURPOSE This study was designed to confirm the efficacy and safety of picoplatin, a cisplatin analog designed to overcome…
Expand
Review
2007
Review
2007
The resurgence of platinum-based cancer chemotherapy
L. Kèlland
Nature Reviews Cancer
2007
Corpus ID: 205468214
The accidental discovery of the anticancer properties of cisplatin and its clinical introduction in the 1970s represent a major…
Expand
Highly Cited
2006
Highly Cited
2006
Gateways to clinical trials.
M. Bayes
,
X. Rabasseda
,
J. Prous
Methods and findings in experimental and clinical…
2006
Corpus ID: 30340641
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
Review
2000
Review
2000
Modulation of the chemical and biological properties of trans platinum complexes: monofunctional platinum complexes containing one nucleobase as potential antiviral chemotypes
D. Sartori
,
Bernhard Miller
,
U. Bierbach
,
N. Farrell
JBIC Journal of Biological Inorganic Chemistry
2000
Corpus ID: 24860197
Abstract. Replacement of one of the chloride leaving groups in trans-[PtCl2(NH3)(L)] by the nucleobase 9-ethylguanine gives the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE